By using our website you are consenting to our use of cookies in accordance with our Cookie Policy.
I agree

Turn back to


At Nutraceuticals Europe in Madrid, Mythocondro® meets the innovation highlights

February 28th, 2019

Mythocondro®, the non-animal chondroitin sulfate of fermentation origin, is one of the trending ingredient at Nutraceuticals Europe – Summit & Expo, the international Conference forum where the most important scientific and business developments and the debate on trends and innovation are dealt.

Gnosis by Lesaffre (booth #F24) has disclosed the true innovation of Mythocondro® at a speech held during a dedicated “Bone and Joint Session”, in terms of higher bioavailability, proven clinical efficacy, safety, sustainability and ethical sourcing considerations. At the booth, the company presented the innovative finished formulations just launched in the market by its partners.


Obtained through a state-of-the-art and patented fermentation-based manufacturing process, last year Mythocondro® closed the clinical pharmacokinetics characterization in humans, together with the clinical efficacy and safety at low-dose (600 mg/day instead of the current suggested 1200 mg/day); all of these are turning points in the global use of chondroitin sulfate (CS). Moreover, for the first time a CS ingredient is suitable for vegetarians and vegans people and can benefit people with restrictions of use related to religious and supply issues.

At Nutraceuticals Europe, Mythocondro® offers new proven advancements in joint health with a smaller dose, meanwhile guaranteeing clean label and greater purity. One study demonstrates that the “human like” sulfation pattern and the charge density of Mythocondro® influence its capacity to interact with various extracellular molecules and to exert more pronounced chondroprotective effects, than an animal-derived CS. Another study demonstrates how the low dosage of only 600mg of Mythocondro®  for 12 weeks, results in a statistically significant improvement of the conditions linked with knee osteoarthritis, such as reduced pain intensity, increased flexibility, a modification in inflammation markers and an improved quality of life.

Finally, Gnosis by Lesaffre offers support and know-how to companies interested in Mythocondro®, giving formulation, application, analytical and testing assistance and advice to carry out the development process and make the time to market much easier and faster.

We can also offer access to the clinical researchers and experts on Mythocondro® who might shed even greater confidence and support to the marketing and research & development processes.